Maxi Investments CY Ltd Purchases 40,000 Shares of uniQure N.V. $QURE

Maxi Investments CY Ltd acquired a new stake in uniQure N.V. (NASDAQ:QURE) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 40,000 shares of the biotechnology company’s stock, valued at approximately $966,000. Maxi Investments CY Ltd owned approximately 0.06% of uniQure at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. IFP Advisors Inc grew its stake in shares of uniQure by 18.0% in the third quarter. IFP Advisors Inc now owns 3,280 shares of the biotechnology company’s stock valued at $79,000 after acquiring an additional 500 shares in the last quarter. Activest Wealth Management acquired a new stake in uniQure in the 3rd quarter worth about $121,000. Assenagon Asset Management S.A. raised its stake in uniQure by 35.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 693,693 shares of the biotechnology company’s stock worth $16,760,000 after purchasing an additional 180,163 shares in the last quarter. Sanders Morris Harris LLC acquired a new stake in uniQure in the 3rd quarter worth about $468,000. Finally, Two Seas Capital LP bought a new stake in uniQure in the 3rd quarter valued at about $31,988,000. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Trading Down 3.5%

QURE stock opened at $21.65 on Tuesday. uniQure N.V. has a 52 week low of $8.73 and a 52 week high of $71.50. The business has a 50-day simple moving average of $36.97 and a 200 day simple moving average of $29.65. The company has a quick ratio of 10.01, a current ratio of 10.01 and a debt-to-equity ratio of 0.15.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.40). uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%. The firm had revenue of $5.84 million for the quarter, compared to analyst estimates of $5.45 million. During the same quarter in the previous year, the company earned ($0.69) earnings per share. Equities research analysts predict that uniQure N.V. will post -3.82 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

QURE has been the topic of a number of analyst reports. Wolfe Research upgraded shares of uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 target price on the stock in a research report on Wednesday, July 29th. Royal Bank Of Canada dropped their price target on shares of uniQure from $65.00 to $48.00 and set an “outperform” rating for the company in a research report on Friday, October 2nd. The Goldman Sachs Group cut their price target on uniQure from $46.00 to $31.00 and set a “neutral” rating for the company in a research note on Wednesday, September 30th. UBS Group reissued a “buy” rating and set a $48.00 price target (up from $27.00) on shares of uniQure in a research report on Thursday, October 15th. Finally, William Blair upgraded uniQure to a “strong-buy” rating in a research note on Wednesday, September 23rd. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $53.25.

About uniQure

uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) vectors and other genetic medicine technologies to deliver therapeutic genes intended to address the underlying causes of disease.

uniQure’s best-known product is HEMGENIX, a gene therapy for adults with hemophilia B caused by factor IX deficiency. HEMGENIX was developed by uniQure and is commercialized by CSL Behring under a global licensing agreement.